We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Phio Pharmaceuticals Corp (PHIO) USD0.0001

Sell:$0.72 Buy:$0.76 Change: $0.1 (15.15%)
Market closed |  Prices as at close on 20 February 2024 | Switch to live prices |
Change: $0.1 (15.15%)
Market closed |  Prices as at close on 20 February 2024 | Switch to live prices |
Change: $0.1 (15.15%)
Market closed |  Prices as at close on 20 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) INTASYL therapeutic platform. Its INTASYL compounds are designed to precisely target specific proteins that reduce the body’s ability to fight cancer without the need for specialized formulations or drug delivery systems, and are designed to make immune cells effective in killing tumor cells. Its lead product candidate, PH-762, is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. Its second product candidate, PH-894, is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby effecting the immune system as well as the tumor.

Contact details

257 Simarano Dr Ste 101
United States
+1 (508) 7673861

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.61 million
Shares in issue:
2.44 million
United States
US dollar

Key personnel

  • Robert Bitterman
    Chairman of the Board, President, Chief Executive Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.